Hypofractionated IMRT boost radiotherapy

RADIATION2 trials

Sponsors

The Clatterbridge Cancer Centre NHS Foundation Trust, The Greater Poland Cancer Centre

Conditions

Prostate Cancer

Unknown Phase

BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer

CompletedNCT02125175

The Clatterbridge Cancer Centre NHS Foundation TrustProstate Cancer

Start: 2014-01-31End: 2019-09-30Updated: 2019-10-29

Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated

CompletedNCT02300389

The Greater Poland Cancer CentreProstate Cancer

Start: 2011-12-31End: 2019-12-31Updated: 2020-02-06

Related Papers

Long-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial.

2024-08-22

Hypofractionated dose painting IMRT using 20 fractions for intermediate to high-risk localized prostate cancer: Two-year outcome data (BIOPROP20, NCT02125175).

Journal of Clinical Oncology2019-03-011 citations

Twenty Fraction Prostate Radiotherapy with Intra-prostatic Boost: Results of a Pilot Study.

2016-09-2929 citations